Sanofi/Regeneron's Praluent Gets FDA Panel Nod, But Not For Broad Use
This article was originally published in The Pink Sheet Daily
Executive Summary
PCSK9 inhibitor scores FDA advisory committee support for patients with heterozygous familial hypercholesterolemia but splits on extending use to other patients at high CV risk, falling well short of the sponsors' target population.